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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or
not aprepitant is effective in preventing postoperative nausea and vomiting.
STUDY DESIGN: Review of three English language primary randomized controlled
trials from 2012-2014.
DATA SOURCES: Three double-blind, randomized controlled trials comparing oral
aprepitant with placebo. All articles were found using PubMed.
OUTCOMES MEASURED: The three studies measured nausea severity using a verbal
rating system and number of episodes of nausea and vomiting recorded by a blinded
study investigator.
RESULTS: Vallejo et al found that 29.7% of the patients in the placebo group vomited
compared to 9.3% of the patients who received aprepitant (p = 0.003). They also found
that the worst VRS nausea score was a 5 out of 10 in the group of patients who received
aprepitant versus 8 out of 10 for the placebo group (p = 0.014). Jung et al found that the
groups that received aprepitant had a 35% incidence of nausea compared to 63% in the
placebo group (p = 0.0025). In addition, the aprepitant groups both had 0% incidence of
vomiting compared to the placebo group, which had a 20% incidence (p = 0.005). Sinha
et al found that incidence of vomiting at 72 hours was 3.1% in the experimental group
and 15.0% in the placebo group (p = 0.021). In all of the studies, mean VRS nausea
scores were lower but were not found to be statistically significant.
CONCLUSIONS: Aprepitant is effective in preventing incidence of nausea and
vomiting, but is not found to significantly decrease average nausea rating scores.
KEY WORDS: Postoperative nausea and vomiting, aprepitant
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INTRODUCTION
Postoperative nausea and vomiting (PONV) is one of the most common
complications after undergoing surgery with general anesthesia1. Symptoms can range
from mild nausea to multiple episodes of severe vomiting. This can be distressing to
patients and may result in electrolyte imbalances, dehydration, and hypovolemia2.
Extensive retching and vomiting can also lead to other severe complications such as
aspiration, gastric bleeding, and wound hematomas3. In addition, PONV can delay oral
intake of drugs, fluids, and food4.
Studies have shown that PONV negatively impacts quality of life, and results in
delayed recovery after surgery4. This can lead to prolonged stay in the post-anesthesia
care unit (PACU) or even hospital admission. Prolonged hospital stays only add to the
already expensive cost of surgery, as well as being distressing to the patient and
increasing morbidity5. A single episode of nausea and/or vomiting costs about $22 in
addition to the extra costs associated with a longer hospital stay.
PONV can affect up to 30% of patients undergoing general anesthesia, and this
number can reach up to 80% if the patient has risk factors such as female gender, opioid
use, or non-smoking status1. In addition, longer duration of anesthesia also increases risk
of PONV6.
It is thought that the cause of PONV is multifactorial. Two of the main causes
include opioid induced emesis and inhalational anesthesia induced emesis4. There are
many neurotransmitters involved in this process such as 5-HT, dopamine, and
neurokinin-1 (NK1)4. These neurotransmitters have receptors in the chemoreceptor
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trigger zone in the brain, and imbalances can result in nausea and vomiting in the
postoperative period4.
Antiemetic medications are used before or during surgery to prevent PONV. The
serotonin receptor antagonist ondansetron is most commonly used. Histamine receptor
antagonists including dimenhydrinate and promethazine and dopamine receptor
antagonists including metoclopramide are also used. Dexamethasone, a corticosteroid, is
less commonly used but can also be successful. Non-medical treatment includes
acupuncture6. While these agents are all effective, there is not one medication that works
universally for all patients1.
A new class of antiemetics, NK1 receptor antagonists, has emerged in recent
years and has been used in preventing nausea and vomiting both in postoperative as well
as chemotherapy patients. They work by blocking substance P from binding at the NK1
receptors in the dorsal vagal complex and area postrema, which are both central emetic
pathways7. Aprepitant is currently the only NK1 receptor antagonist on the market and
currently it is mostly being used for chemotherapy-induced nausea and vomiting. It has a
half life of 9 to 12 hours, which makes it longer acting than the more commonly used
serotonin receptor antagonists8. Adverse effects are mild and may include fatigue,
diarrhea, or dizziness9.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not
aprepitant is effective in preventing postoperative nausea and vomiting.
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METHODS
This paper evaluates three double blind randomized control trials comparing
efficacy of aprepitant as a medication for improving nausea and vomiting in patients
postoperatively. All three studies were chosen using the same criteria. The population
included patients that have undergone surgery with general anesthesia and the
interventions included 40, 80, or 125 mg of oral aprepitant. All three studies used patients
who had at least 2 of the following risk factors for PONV: female gender, nonsmoker,
history of motion sickness or previous PONV, and use of postoperative opioids. The
treatment group receiving aprepitant was compared an experimental group which
received a placebo. The outcomes measured were the effect of aprepitant on the incidence
of nausea and vomiting as well as the effect of aprepitant on the severity of nausea.
Finally, all three trials were randomized, double blind clinical trials.
All articles were written in English and published in peer reviewed journals. They
were selected from Pubmed in 2015 by the author using the keywords “aprepitant” and
“postoperative nausea and vomiting.” The articles were chosen based on relevance and
that the outcomes of the studies were patient oriented (POEMs). Inclusion criteria
included randomized, double blind controlled trials with patients over the age of 18 and
exclusion criteria included articles published before 1996 and patients that did not
undergo general anesthesia. All articles were published between 2012 and 2014 and have
similar demographics and characteristics (Table 1). The statistics reported or used in the
studies were control event rate (CER) and experimental event rate (EER), relative risk
reduction (RRR), absolute risk reduction (ARR), number needed to treat (NNT), odds
ratio (OR), and p-value.

Gomberg, Aprepitant and Nausea and Vomiting

4

Table 1. Demographics & Characteristics of included studies
Study

Type

# Pts

Age
(yrs)
18-65
years

Vallejo
(2012)1

Double
blind
RCT

150

Jung
(2013)7

Double
blind
RCT

123

21-60
years

Sinha
(2014)8

Double
blind
RCT

125

18
years
or
older

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Patients 18-65
years with
American Society
of Anesthesiology
(ASA) 1 to III
status who are
considered high
risk for PONV
and were
undergoing
ambulatory
plastic surgery
under general
anesthesia for at
least 1-hour
Patients 21-60
years considered
high risk for
PONV scheduled
for elective
laparoscopic total
hysterectomy
with ASA I to II
status

Patient refusal,
received other
antiemetics before
procedure, history
of allergy or
sensitivity to study
drugs, pregnancy,
history of chronic
opioid use

1

40 mg of oral
aprepitant plus
4 mg of IV
ondansetron or
oral placebo
plus 4 mg of
IV
ondansetron

Liver, neurologic,
and active
pulmonary disease,
cardiac
arrhythmia,
allergies to any
perioperative
medications used
in the study

0

Preoperative
80 mg oral
aprepitant; pre
Operative 125
mg oral
aprepitant; or
placebo (10
mL saline)

Patients over 18
years considered
high risk for
PONV who are
morbidly obese
and undergoing
elective
gastrointestinal
surgery with ASA
I to III status

Allergy to
ondansetron or
aprepitant,
pregnant or
breastfeeding,
substance abuse or
significant
psychiatric
disease, history of
chronic
nausea/vomiting,
taking any
medication with
known antiemetic
properties or
known interaction
with study drugs

1

80 mg oral
aprepitant and
4 mg
ondansetron or
placebo tablet
and 4 mg
ondansetron
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OUTCOMES MEASURED
All three studies measured the severity of nausea as well as the incidence of
nausea and vomiting. Severity of nausea was measured by the patient using a verbal
rating scale (VRS) where 0 represented no nausea and 10 represented worst possible
nausea. Incidence of nausea and vomiting was measured by a blinded study investigator.
In the study by Vallejo et al, patients also recorded incidence of nausea and vomiting at
home once they were discharged from the hospital1. All of the studies considered patients
to have a complete response if they had no nausea, retching, or vomiting during the
postoperative period.

RESULTS
Vallejo et al enrolled 150 patients between the ages of 18 and 65 with American
Society of Anesthesiology (ASA) I to III status who were undergoing plastic surgery with
general anesthesia and had 2 or more risk factors for PONV1. Exclusion criteria included
patient refusal, receiving other antiemetics before procedure, history of allergy or
sensitivity to study drugs, pregnancy, and history of chronic opioid use. Patients either
received 40 mg of oral aprepitant plus 4 mg of intravenous ondansetron or oral placebo
plus 4 mg intravenous ondansetron. The aprepitant or placebo was administered within 2
hours before the procedure, and the ondansetron was administered at the start of
anesthesia. One patient was lost to follow up after discharge, but their results in the
hospital were still included in analysis. Patients rated their nausea severity every 4 hours
for the first 24 hours after surgery, and then every 8 hours the second 24 hours.
Occurrence of vomiting was recorded hourly until discharge. Intention-to-treat analysis
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was performed. They found that 29.7% of the patients in the placebo group vomited
compared to 9.3% of the patients who received aprepitant (p = 0.003) with a risk
reduction of 31.3% (95% CI, 14.3-69.0%) In addition, they found that all of the episodes
of vomiting occurred in the first 12 hours after surgery. They also found that the worst
VRS nausea score, defined as the highest score reported by the patient in the 48 hours,
was a 5 out of 10 in the group of patients who received aprepitant versus 8 out of 10 for
the placebo group (p = 0.014). The mean VRS nausea scores were also higher in the
placebo group, however it was not significant (p = 0.24). Complete response occurred in
26 patients in the experimental group and 20 patients in the control group but this was
also not significant (p=0.288)1.
Statistical analysis of incidence of vomiting for all three RCTs can be found in
table 2. For the study conducted by Vallejo et al, relative risk reduction (RRR) was found
to be -69.0%, and absolute risk reduction (ARR) was found to be -20.4%. Number
needed to treat (NNT) was calculated to be -4. This means that for every 4 patients
treated with aprepitant, one fewer patient vomited than if they had received the placebo.
Jung et al selected patients age 21-65 years with ASA status I or II undergoing
elective laparoscopic total hysterectomy7. Patients were also considered high risk for
PONV, using the same criteria as Vallejo et al. Exclusion criteria included liver,
neurologic, and active pulmonary disease, cardiac arrhythmia, and allergies to any
perioperative medications used in the study. Patients were randomly divided into three
groups of 40 and either received 80 mg aprepitant, 125 mg aprepitant, or 10 mL normal
saline as placebo. The aprepitant or placebo was administered 2 hours before anesthesia.
Patients were assessed at 2 hours, 24 hours, and 48 hours, and any episodes of nausea and
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vomiting were recorded throughout that time period. Both of the groups that received
aprepitant had a 35% incidence of nausea compared to 63% in the placebo group (p =
0.0025). In addition, the aprepitant groups both had 0% incidence of vomiting compared
to the placebo group, which had a 20% incidence (p = 0.005). The difference between the
80 mg and 125 mg aprepitant groups was not significant. The peak VRS nausea scores
were 6 out of 10 for the placebo group, and 4 out of 10 in both aprepitant groups, but this
data is not statistically significant. Complete response during the first 48 hours after
surgery was seen in 28% of the control group, 56% of the 80 mg aprepitant group, and
63% of the 125 mg aprepitant group. Both 80 mg and 125 mg aprepitant groups were
found to be significantly higher than the control group (p = 0.007 and p = 0.004
respectively)7.
For the study conducted by Jung et al, RRR was found to be -100.0%, and ARR
was found to be -20.0%. NNT was calculated to be -5. This means that for every 5
patients treated with aprepitant, one fewer patient vomited than if they had received the
placebo.
Jung et al also recorded the incidence of adverse effects. Patients in all three
groups reported adverse effects including dizziness, headache, dyspepsia, and abdominal
distension. The symptoms were all mild and no patients required additional treatment.
There was no statistical significance of incidence of adverse effects between control and
experimental groups7.
Sinha et al enrolled 125 patients aged 18 years or above, were morbidly obese,
ASA status I to III, and considered high risk for PONV8. Exclusion criteria included
allergy to ondansetron or aprepitant, pregnant or breastfeeding, substance abuse or
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significant psychiatric disease, history of chronic nausea/vomiting, and taking any
medication with known antiemetic properties or known interaction with study drugs. One
patient was lost from the placebo group during surgery. Patients either received 80 mg
oral aprepitant and 4 mg IV ondansetron or placebo tablet and 4 mg IV ondansetron. The
aprepitant tablet or placebo tablet was administered 1 hour before surgery, and IV
ondansetron was administered to every patient just before the end of surgery. Nausea
severity scores were recorded during the postoperative period at 3 minutes, 1, 2, 6, 24,
48, and 72 hours. Any episode of vomiting was also recorded. Incidence of vomiting at
72 hours was 3.1% in the group that received aprepitant, which was significantly lower
than the placebo group which had an incidence of 15.0% (p = 0.021, 95% CI, 5.6724.30%). The odds ratio (OR) of an episode of vomiting in the control group compared to
the experimental group was 5.47 times (p = 0.026, 95% CI, 1.31-26.46). The results for
mean VRS nausea scores were not statistically significant. Complete response was seen
in 27 patients (42.18%) in the experimental group and in 22 patients (36.67%) in the
control group, but this was also not statistically significant (p = 0.510)8.
For the study conducted by Sinha et al, RRR was found to be -79.3%, and ARR
was found to be -11.9%. NNT was calculated to be -8. This means that for every 8
patients treated with aprepitant, one fewer patient vomited than if they had received the
placebo.
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Table 2. Statistical Analysis of Oral Aprepitant vs. Placebo Effect on Incidence of
Vomiting
Study

Vallejo et al
(2012)1
Jung et al
(2013)7
Sinha et al
(2014)

Control
Event
Rate
(CER)
29.7%

Experimental Relative Risk
Event Rate
Reduction
(EER)
(RRR)
-69.0%

Absolute
risk
reduction
(ARR)
-20.4%

Number
Needed to
Treat
(NNT)
-4

9.3%

20.0%

0.0%

-100%

-20%

-5

15.0%

3.1%

-79.3%

-11.9%

-8

DISCUSSION
All three studies showed a significant decrease in the incidence of postoperative
vomiting with oral aprepitant compared to placebo. In addition, Jung et al also showed a
significant decrease in the incidence of nausea with aprepitant. Peak nausea rating score
was significantly higher as reported by Vallejo et al, although the other studies failed to
get significant results. Mean VRS nausea scores appeared to decrease with aprepitant, but
none of the studies had statistically significant results.
The main limitation of the use of aprepitant is the cost. Since it is a newer drug, it
is substantially more expensive than the older, more commonly used agents. Vallejo et al
reported that the cost of aprepitant at their institution was $46.60 compared to $0.60 for
ondansetron1. While aprepitant is considerably more costly than ondansetron, it must be
considered that an extended hospital stay and extra care required for patients with severe
nausea and vomiting postoperatively could incur an even higher cost. Patients would
likely be willing to pay the extra cost of aprepitant to avoid the potential complications
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longer stay at the hospital.
There are also some limitations of the studies themselves. Vallejo et al reports that
a limitation of their study was the timing of the administration of ondansetron1. Previous
studies show that ondansetron is most effective when given near the end of surgery1. In
this study, the ondansetron was given at the beginning of surgery to account for the
variation in surgery duration between patients1. Jung et al did not study doses of
aprepitant less than 80 mg7. In addition, they did not calculate a cost-effectiveness
analysis7. Finally, Sinha et al reports that they did not compare opioid between the
control and experimental groups8. Since opioids increase risk of nausea and vomiting,
this could have affected the results.

CONCLUSION
Based on this systematic review of three randomized controlled trials, aprepitant
is effective in preventing the incidence of nausea and vomiting; however it is not shown
to be significantly effective in reducing the severity of nausea if it occurs. Even though
the cost may present a problem for some patients, aprepitant has the potential to reduce
postoperative complications from excessive vomiting and lead to shorter hospital stays.
This not only reduces overall cost, but could also improve quality of life in patients
during the postoperative period. Future studies should be focused toward comparing
aprepitant to the commonly used antiemetics for PONV such as ondansetron or
metoclopramide. In addition, it would be also advantageous to investigate the use of
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aprepitant for other causes of nausea and vomiting since it is effective and has mild
adverse effects.
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